Biotech Funds: Invest in the Medicines of Tomorrow
Biotech companies with exceptional growth potential
Are you looking to invest in a biotech fund that invests in fast-growing, publicly traded biotech companies? The 2 Aescap funds invest in companies with breakthrough treatments for diseases like Alzheimer’s, cancer, MS, Parkinson’s and other diseases with a high unmet medical need.. Both funds targets an average annual return of 20% over the medium term. The Aescap biotech funds offer both high growth potential and a powerful societal impact.
Our investment team selects the most promising undervalued companies for the Aescap Life Sciences fund and the Aescap Genetics Fund based on fundamental analysis and intensive interaction with management. Our team members are highly experienced, have an excellent track record, and also invest significantly in the Aescap funds themselves. The funds’ AIFM is supervised by the AFM and DNB.
The name Aescap is derived from ‘Aesculapius’, the Roman god of medicine, and ‘capital’.
Biotech’s long-term Growth
- Aging population creates explosive demand
- AI is accelerating medicine development
- 2 billion new users from emerging markets
Why choose the Aescap funds
- Focused on High Potential. From a universe of over 1,000 listed biotech firms, we select the top 75 most promising candidates annually. From that shortlist, we build a concentrated portfolio of around 20 companies—each carefully chosen based on robust fundamentals.
- Diversified & Disciplined. Our strategy balances focused conviction with smart diversification across disease areas, development stages, and regions. We actively manage our entry and exit points, ensuring every position is monitored with strict discipline.
- Skin in the Game. The investment team with highly experienced professional have invested over € 30 million in the Aescap funds. Demonstrating our strong commitment to and confidence in the funds.
- Proven, Active Management. We operate with a high-conviction approach. Our investment process is fundamental and hands-on, constantly tracking portfolio performance, scientific milestones, and market developments.
- Solid structure. Our investment team is overseen by a risk and compliance manager, as well as by various external parties such as the Netherlands Authority for the Financial Markets (AFM) and Apex Depositary Services.
Subscribe to our newsletter
Double Return
At Aescap, we invest in listed biotech companies with exceptional growth potential. Companies pioneering the future of medicine. Our mission is to deliver excellent returns while making a significant impact on global health.
That’s why both the Aescap Life Sciences fund and the Aescap Genetics fund are classified under Article 8 of the EU Sustainable Finance Disclosure Regulation (SFDR).
Investment Strategy
- Next-generation medicine
- Outstanding management
- High-growth companies
- Diversification within our focus
- Undervalued companies
- Buy and Sell discipline
Update via webcast
Aescap organizes a webcast after every quarter to inform existing and potential investors about developments in our 2 funds. The next webcast will take place on January 22 at 3 p.m.
Interested in investing with Aescap? Contact us today to arrange an exploratory meeting: call us on 020 570 2940 or send an email.
Latest news
Acquisition of Avidity by Novartis for $ 12 billion.
Novartis and Avidity announced that the boards of directors of Avidity Biosciences and Novartis have agreed to the acquisition of Avidity for $72 per share, representing a total consideration of approximately $12 billion. The $72 per share offer represents a premium of approximately 46% over Avidity’s closing price on October 24 of $49.15 and approximately
+248% for portfolio company Uniqure
Uniqure presented unprecedented pivotal clinical trial data for Huntington’s disease yesterday. It demonstrated a statistically significant 75% disease slowing of this devastating disease. This is life-changing news for people suffering from this devastating disease for which no treatment is available today. We expect the medicine to reach patients in the US first by late 2026.
5 game changing products from the Aescap portfolio
Innovation in medicine R&D is gearing up rapidly, with over 20 new technologies being added over the years and AI improving timelines, costs, and success rate. We picked some eye-opening products from our portfolio companies that have been launched recently or delivered great results in clinical trials Sickle cell disease Crispr Therapeutics recently launched the